Financial Performance - The group recorded revenue of SGD 2.8 million for the three months ended March 31, 2019, representing an increase of approximately 10.5% compared to SGD 2.6 million for the same period in 2018[6]. - The net profit for the period was approximately SGD 0.3 million, unchanged from the previous year, primarily due to increased employee and operating expenses offsetting revenue growth[6]. - The group reported a gross profit of SGD 323,000 for the period, slightly up from SGD 307,000 in the previous year[9]. - Total comprehensive income attributable to owners of the company for the period was SGD 268,000, compared to SGD 255,000 in the previous year[9]. - Revenue increased by approximately SGD 0.3 million or 10.5% year-on-year, reaching about SGD 2.8 million for the quarter ended March 31, 2019[31]. - Net profit attributable to owners was approximately SGD 0.3 million, consistent with the same period last year[35]. - Earnings per share decreased to 0.05 Singapore cents from 0.06 Singapore cents year-on-year, with issued shares increasing from 390 million to 520 million[25]. Expenses and Costs - Employee benefits expenses increased to SGD 916,000 from SGD 713,000 in the previous year, reflecting higher operational costs[9]. - Employee benefits expenses rose by approximately SGD 0.2 million or 28.5% to about SGD 0.9 million, primarily due to hiring for new treatment centers[33]. - Other operating expenses increased by approximately SGD 0.3 million, attributed to higher marketing and legal costs post-IPO[34]. Dividends and Equity - The company did not declare any dividends for the period, consistent with the previous year[7]. - The company has no bank borrowings and maintains a strong liquidity position with no significant contingent liabilities[39][43]. - The company’s total equity as of March 31, 2019, was SGD 12.84 million, an increase from SGD 12.57 million at the beginning of the year[11]. - No dividends were declared for the period, consistent with the previous year[36]. Business Operations and Expansion - Medical services revenue included SGD 1.7 million from treatment services, SGD 0.9 million from medical examination services, and SGD 0.3 million from consultation services[19]. - The company opened two new treatment centers during the period, expanding its network under the "Dr. Tan & Partners" brand[27]. - The group continues to focus on expanding its healthcare services in Singapore, leveraging its existing facilities and expertise[14]. Compliance and Governance - The financial statements were prepared in accordance with International Financial Reporting Standards and GEM listing rules, ensuring compliance and transparency[15]. - The company has complied with all applicable corporate governance codes as per GEM Listing Rules[60]. - The audit committee, consisting of three independent non-executive directors, has reviewed the financial statements and found them compliant with applicable accounting standards[65]. - There were no interests held by directors or controlling shareholders in any competing businesses during the reporting period[58]. Shareholding Structure - As of March 31, 2019, the company had a total of 520,000,000 shares issued[52]. - Dr. Chen holds 390,000,000 shares, representing 75% of the company's issued shares[56]. - Cher Sen Holdings Limited, controlled by Dr. Chen, owns 390,000,000 shares, also accounting for 75% of the issued shares[56]. - Dr. Chen is the beneficial owner of 50,000 shares in Cher Sen, representing 100% of that entity[53]. - No other entities, apart from those disclosed, held any significant interests in the company's shares as of March 31, 2019[57]. Other Information - The company has not disclosed any new product developments or market expansions in the provided documents[64]. - No securities were repurchased or sold by the company during the reporting period[63]. - The management emphasizes ongoing investment in technology to maintain competitive advantages, particularly in the medical aesthetics sector[28].

Financial Performance - The group's revenue for the fiscal year ended December 31, 2018, was approximately SGD 10.4 million, an increase of about 4.7% compared to SGD 10.0 million for the fiscal year ended December 31, 2017[10]. - The group recorded a loss of approximately SGD 0.7 million for the fiscal year, compared to a profit of SGD 2 million in the previous fiscal year, primarily due to non-recurring listing expenses of about SGD 2.1 million[10]. - Adjusted profit for the fiscal year was approximately SGD 1.4 million, down from SGD 2.7 million in the previous fiscal year, mainly due to costs incurred post-listing[10]. - The group's total revenue for the year was approximately SGD 10,421,000, an increase of about SGD 465,000 or 4.7% compared to SGD 9,957,000 in FY2017[16]. - Revenue from medical examination services increased by SGD 100,000 to SGD 3,017,000, maintaining a stable contribution percentage of 29%[19]. - Revenue from treatment services rose by SGD 800,000 to SGD 6,263,000, with its contribution percentage increasing from 54.8% in FY2017 to 60.1% in FY2018[19]. - The group recorded a loss of approximately SGD 731,000 for the year, a decline of about SGD 2.7 million compared to a profit of SGD 2 million in FY2017[34]. - Listing expenses totaled approximately SGD 3.9 million for the year, significantly up from SGD 743,000 in FY2017[35]. - The group did not declare a final dividend for the year, following a total dividend distribution of approximately SGD 2.2 million in FY2017[38]. Revenue Breakdown - Revenue from consultation services, treatment services, and medical examination services were approximately SGD 1.1 million, SGD 6.3 million, and SGD 3.0 million, respectively, accounting for 10.1%, 60.0%, and 29.0% of total revenue[15]. Expenses and Costs - Employee benefits expenses increased by SGD 861,000 or 30.8% to SGD 3,659,000 due to an increase in the number of employees[26]. - Other operating expenses grew by approximately SGD 1,788,000 or 87.8% to about SGD 3,825,000, largely due to increased listing expenses[30]. - Employee costs for the year amounted to approximately SGD 3.7 million, up from SGD 2.8 million in the fiscal year 2017[47]. Assets and Equity - Total equity as of December 31, 2018, was approximately SGD 12.6 million, up from SGD 1.7 million in the fiscal year 2017[39]. - Cash and bank balances as of December 31, 2018, were approximately SGD 12.4 million, compared to SGD 2.0 million in the fiscal year 2017[39]. - Net current assets as of December 31, 2018, were approximately SGD 11.7 million, an increase from SGD 876,000 in the fiscal year 2017[39]. - The capital debt ratio as of December 31, 2018, was 0.0%, consistent with the fiscal year 2017[39]. Future Plans and Expansion - The net proceeds from the listing amounted to approximately SGD 9.1 million, which will be used for future expansion and business growth in Singapore[11]. - The company aims to expand its market share and enhance the DTAP brand reputation in the competitive healthcare services industry in Singapore[15]. - The company has delayed the opening of a new DTAP clinic in western Singapore to mid-2019 due to the availability of suitable rental space, with approximately SGD 1.1 million from the IPO proceeds remaining unutilized[61]. - The company has begun the design work for IT infrastructure and systems for the clinics, having selected suppliers and paid a deposit of SGD 57,000[63]. - The company has identified Holland Village as a suitable location for the new DTAP clinic, with renovations planned[63]. Governance and Leadership - The company has a strong governance structure with independent non-executive directors overseeing key committees such as audit, nomination, and remuneration[76][78]. - The company has established a strong foundation for future growth with experienced leadership in both medical and financial sectors[81][82]. - The board includes members with diverse backgrounds in finance, healthcare, and technology, contributing to a well-rounded strategic direction[76][82]. - The independent directors provide independent judgment on strategies, policies, and accountability standards, ensuring robust governance[76][78]. - The company is committed to maintaining high standards of corporate governance and regularly reviews its practices[146]. Committees and Meetings - The company has established three committees: Audit Committee, Nomination Committee, and Remuneration Committee, to oversee specific aspects of its affairs[186]. - The Audit Committee monitors the integrity of the company's financial statements and reviews significant judgments related to financial reporting[190]. - The Nomination Committee is tasked with reviewing the company's corporate governance policies and practices, making recommendations to the board[195]. - The Remuneration Committee reviewed matters related to the remuneration of directors and senior management during a meeting on March 27, 2019, providing recommendations to the board[199]. Shareholder Information - As of December 31, 2018, a director held 390 million shares, representing 75% of the company's issued shares, through a controlled corporation[135]. - The company maintains a sufficient public float, with at least 25% of its issued shares held by the public[148]. - The company has not repurchased any of its listed securities during the period[108].